About Idera
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.
Idera’s TLR programs include:
- Infectious diseases: IMO-2125 for hepatitis C virus infection
- Autoimmune diseases: TLR antagonists in preclinical stage
- Oncology: TLR7 and 8 in preclinical stage
- Respiratory diseases: partnered with Novartis International Pharmaceutical, Ltd.
- Vaccine adjuvants: partnered with Merck & Co. Inc.
- Cancer Treatment: partnered with Merck KGaA
Idera is located in the Cambridge, Massachusetts biotechnology cluster and has a team of approximately 40 dedicated professionals.
Idera common shares trade on the Nasdaq Global Market under the symbol IDRA.